Search

FDA and EMA guidance now call for endpoints that capture the full picture of patient well-being, including physical, psychological, and social. If your obesity trials aren't incorporating this multidimensional approach, ...

Identifying the differences between the clinical development processes for pediatric trials and adult trials can be difficult, especially when resources are constrained. Watch our recent webinar where Heather Peterson an...

AI-enabled medical devices are transforming healthcare, but the regulatory path remains complex. Did you know the FDA has approved over 1,000 AI-enabled devices since 2015, yet there’s still no distinct regulatory route?...

ICON has been named as one of the TIME World's Best Companies in Sustainable Growth 2025. As an organisation that places a great deal of emphasis on #ESG, having our #ICONCares initiative recognised on a global scale i...

Last Thursday, colleagues from our Barcelona office came together for the first edition of the ICON Run4Health, organised by our Barcelona Volunteering Team. Team members took part in a 5K run or walk to raise funds for...

Antimicrobial resistance is a growing global threat, making traditional antibiotics less effective. ICON’s latest article explores how bacteriophage therapy—a virus-based approach—could help tackle multidrug-resistant in...

Everything you need to make the important decision of where to publish your work. 50+ metadata consideration points including deadlines and lead times. Links to author submission guides fast and easy. Request a demo. htt...

Join us for a focused discussion on early phase clinical trial strategies in neurodegenerative disease therapeutics. This session hosted by ASCPT will explore key considerations and share examples from studies in neurode...

ICON is at the World Drug Safety Congress in Boston. Visit us at booth \#227 to learn how ICON is advancing innovation in drug safety and pharmacovigilance. Our experts will share insights on risk management, patient s...

Recently, 132 of ICON’s biopharma sponsors shared insights on the evolution of clinical monitoring. Our new whitepaper highlights the benefits: faster enrolment, reduced site burden and strategic CRA support. Read more: ...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Are your trials measuring what matters to patients…or just what’s easiest to capture? It’s no longer enough to only drive outcomes. Rather, we must drive outcomes that matter to patients. In this whitepaper, we outlin...